Hikma partners with Pharmaand to market Rucaparib in MENA

JORDAN—Hikma Pharmaceuticals PLC, a leading multinational pharmaceutical company, has announced a significant partnership with pharmaand GmbH (pharma&), a global pharmaceutical firm based in Vienna, Austria.

Hikma has secured the rights to market rucaparib in the Middle East and North Africa (MENA) region through this exclusive licensing agreement.

 This development marks a major milestone in Hikma’s efforts to expand its oncology portfolio and address critical healthcare needs in the region.

Rucaparib, sold under the brand name Rubraca®, is an innovative oral therapy that targets poly (ADP-ribose) polymerases (PARPs)—proteins essential for DNA repair in cancer cells.

 By inhibiting these proteins, rucaparib plays a vital role in treating ovarian and prostate cancers.

Ovarian cancer is the eighth most common cancer among women worldwide, while prostate cancer ranks as the fourth most common cancer globally and the second most prevalent among men.

The drug has already received regulatory approval from both the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA), underscoring its efficacy and safety.

Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA, expressed enthusiasm for the partnership, highlighting rucaparib’s potential to transform oncology care in the region.

 He emphasized that adding this innovative treatment to Hikma’s portfolio aligns with the company’s mission to enhance access to life-changing therapies.

Darwazah stated that this agreement represents a significant step forward in addressing unmet medical needs while improving patient outcomes.

The introduction of rucaparib also strengthens Hikma’s commitment to advancing cancer care and supporting its broader purpose of making better health accessible daily.

As the company’s first FDA- and EMA-approved small-molecule oral therapy for oncology, rucaparib reinforces Hikma’s dedication to providing cutting-edge treatments that save lives.

This collaboration not only expands Hikma’s presence in oncology but also demonstrates its ongoing efforts to deliver advanced therapies to patients across MENA.

By prioritizing innovation and accessibility, Hikma continues to position itself as a leader in pharmaceutical care, ensuring that patients battling serious illnesses have access to effective treatment options.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.